期刊文献+

司维拉姆与慢性肾脏病高磷血症患者的临床预后 被引量:11

下载PDF
导出
摘要 高磷血症广泛存在于慢性肾脏病(chronic kidney disease,CKD)尤其是终末期肾脏病(endstage renal disease,ESRD)患者中。目前我国血液透析患者的高磷血症患病率近60%,而血磷控制的达标率只有38.5%,与欧美相比还有较大差距。进一步的研究显示,高磷血症与终末肾脏病冠状动脉钙化的发生发展密切相关,已被越来越多的研究证实是ESRD心血管事件和死亡的关键危险因素之一,因此,有效控制维持性血液透析患者的血磷水平,纠正矿物质和骨代谢异常,进而改善患者的生存质量,减少远期心血管事件风险,一直是肾病学家关注的热点。
出处 《中国血液净化》 2014年第6期469-471,共3页 Chinese Journal of Blood Purification
  • 相关文献

参考文献27

  • 1Kong X,Zhang L,Zhang L,et al.Mineral and bone disor-der in Chinese dialysis patients:a multicenter study [J].BMC Nephrol,2012,13:116.
  • 2Block G A,Klassen P S,Lazarus J M,et al.Mineral me-tabolism,mortality,and morbidity in maintenance hemo-dialysis[J].J Am Soc Nephrol,2004,15:2208-2218.
  • 3Kendrick J,Chonchol M.The role of phosphorus in the development and progression of vascular calcification [J].Am J Kidney Dis,2011,58:826-834.
  • 4Palmer S C,Hayen A,Macaskill P,et al.Serum levels of phosphorus,parathyroid hormone,and calcium and risks of death and cardiovascular disease in individu-als with chronic kidney disease a systematic review and meta-analysis[J].JAMA:the journal of the Ameri-can Medical Association,2011,305:1119-1127.
  • 5Chertow G M,Levin N W,Beck G J,et al.In-center he-modialysis six times per week versus three times per week[J].The New England journal of medicine,2010,363:2287.
  • 6Fan S,Ross C,Mitra S,et al.A randomized,crossover design study of sevelamer carbonate powder and sevelam-er hydrochloride tablets in chronic kidney disease pa-tients on haemodialysis[J].Nephrol Dial Transplant,2009,24:3794-3799.
  • 7Fishbane S,Delmez J,Suki W N,et al.A randomized,parallel,open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis[J].Am J Kidney Dis,2010,55:307-315.
  • 8Evenepoel P,Selgas R,Caputo F,et al.Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis[J].Nephrology Dial-ysis Transplantation,2009,24:278-285.
  • 9Kakuta T,Tanaka R,Hyodo T,et al.Effect of sevelam-er and calcium-based phosphate binders on coronary ar-tery calcification and accumulation of circulating ad-vanced glycation end products in hemodialysis patients [J].Am J Kidney Dis,2011,57:422-431.
  • 10Kestenbaam B,Sampson J N,Rudser K D,et al.Serum phosphate levels and mortality risk among people with chronic kidney disease[J].J Am Soc Nephrol,2005,16:520-528.

同被引文献78

  • 1张宁,宋军,刘世巍,陈忠英,任可,安海燕,史颖红.肾性骨病患者生存质量主要影响因素的研究[J].中华中医药杂志,2005,20(5):287-289. 被引量:17
  • 2王梅.透析液钙离子浓度的选择[J].中国血液净化,2006,5(2):59-60. 被引量:9
  • 3高玉春,李孜,唐晓红,刁骧(审校).碳酸镧治疗维持性血液透析患者高磷血症有效性和安全性的系统评价[J].中国循证医学杂志,2006,6(10):727-732. 被引量:12
  • 4江瑛,王梅.高血磷对慢性肾衰竭大鼠血管钙化的影响[J].中华肾脏病杂志,2007,23(10):663-667. 被引量:7
  • 5Batu E, Kesici S, Bayrakci B. Calcium Acetate Treatment tot Hy- perphosphatemia From Ingestion of Fireworks[J]. Pediatric Criti- cal Care Medicine, 2014, 15(4_suppl) : 178 - 179.
  • 6Kalaitzidis RG, Elisaf M S. Hypevphosphatemia and ptmsphate binders: eftectiveness and safety [ J]. Current Medical Research & Opinion, 2013, 30(1) : 109 -112.
  • 7Ruggeri M, Bellasi A, Cipriani F, et al. Sevelamer is cost effective versus calcium carbonate for the first - line treatment of hyperphos- phatemia in new patients to hemodialysis : a patient - level economic e- valuation of the INDEPENDENT- HD study[J]. Journal of nephrolo- gy, 2014:1 -10.
  • 8Bernm'd L,Mendelssohn D ,Dunn E ,et al. A modeled economic evalua- tion of sevelamer for treatment of hyperphosphatemia associated with ehronie kidney disease among patients on dialysis in the United King- dom [ J ]. Journal of medical economies ,2012,16 ( 1 ) : 1 - 9.
  • 9Xu J, Zhang YX, Yu XQ, et al. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in China's Mainland[J].BMC nephrology, 2013, 14( 1 ) : 29.
  • 10Dwyer JP, Sika M, Schulman G, et al. Dose - respunse and effi- cacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short -term randomized trial [ J ]. American Journal of Kidney Diseases. 2013. 61 (5) :759 - 766.

引证文献11

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部